A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity

Area of Science:

• Oncology
• Virology
• Biotechnology

Background:

• Cancer remains a leading cause of death, necessitating novel therapies beyond surgery, chemotherapy, and radiotherapy.
• Oncolytic virotherapy using viruses like measles virus (MV) shows promise but is limited by host immune responses.
• Existing therapies face challenges, driving the need for innovative treatment modalities.

Purpose of the Study:

• To enhance and prolong the antitumor activity of oncolytic virotherapy.
• To evaluate the efficacy of a novel polymer-coated measles virus (MV-NPL) compared to naked MV-NPL.
• To investigate the potential of polymer-coated MV-NPL as a future cancer therapy.

Main Methods:

• Genetically engineered measles virus (MV-NPL) was developed.
• A multilayer virus-coating method using layer-by-layer deposition of ionic polymers was employed.
• Oncolytic effects and antitumor activities were compared between polymer-coated MV-NPL and naked MV-NPL both in vitro and in vivo.

Main Results:

• Polymer-coated MV-NPL demonstrated enhanced oncolytic activity compared to naked MV-NPL in the presence of anti-MV neutralizing antibodies in vitro.
• In vivo studies showed higher complement-dependent cytotoxicity and antitumor activities in mice treated with polymer-coated MV-NPL.
• The polymer coating effectively protected the virus and improved its therapeutic efficacy.

Conclusions:

• The novel, polymer-coated MV-NPL represents a promising advancement in oncolytic virotherapy.
• This approach effectively overcomes limitations posed by host immune responses.
• Polymer-coated MV-NPL holds significant potential for future clinical cancer therapy.